Alteraciones del metabolismo lipídico en pacientes infectados por VIH

Mariela Vacarezza Consani; Rodolfo Vázquez Pedrouzo; Eduardo Savio Larriera

Authors

Mariela Vacarezza Consani Universidad de la República, Facultad de Medicina, Cátedra de Enfermedades Infecciosas, Asistente. Especialista en Medicina Interna. Doctora en Medicina
Rodolfo Vázquez Pedrouzo Universidad de la República, Facultad de Medicina, Departamento de Medicina Preventiva y Social, Prof. Adjunto Titular. Magíster en Epidemiología. Doctor en Medicina
Eduardo Savio Larriera Universidad de la República, Facultad de Medicina, Cátedra de Enfermedades Infecciosas, Profesor. Especialista en Infectología y Medicina Interna. Doctor en Medicina

Keywords:

LIPIDS, ACQUIRED IMMUNODEFICIENCY SYNDROME, HIV INFECTIONS

Abstract

The infection by human immunodeficiency virus (HIV) and its ultimate consequence, Acquired Immune Deficiency Syndrome (AIDS) is an important public health problem, considering the incidence and mortality, social aspects and costs. In Uruguay the infection by this retrovirus is characterized as a controlled epidemic with a prevalence of 0.3%. The antiretroviral therapy transformed this pathology into a chronic and controlled disease. However, lipidic metabolism abnormalities have been observed. The prevalence of dislipemia in patients with HIV is unknown in our country.
This study aimed at comparing the prevalence of lipidic metabolism alterations between patients with HIV and seronegative patients. Other specific objectives included the determination of lipidic alterations in patients with HIV and the associations between antiretroviral therapy drugs and lipidic metabolism complications.
A transversal, descriptive study was conducted in two probabilistic samples: 133 patients with HIV and 133 patients of a control group. Statistic significance of the differences was analyzed by calculations of chi-square.
In accordance with other studies we concluded that infection by HIV, antiretroviral therapy and antiretroviral drugs caused lipidic metabolism complications. Protease inhibitors such as ritonavir and indinavir caused the most severe lipidic alterations.

References

1) Uruguay. Ministerio de Salud Pública. Programa Nacional de Sida. Informe epidemiológico VIH-Sida. Prevalencia actual de infección por VIH. Boletín Epidemiológico. (Montevideo) 2000: 1-10.
2) Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chiísmo DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodistrophy, hyperlipidaemia and diabetes mellitus; a cohort study. Lancet 1999; 353(9170): 2093-9.
3) Kotler DP. Update on metabolic and morphologic abnormalities in HIV. Medscape HIV/AIDS: 1999 Annual Update. (www.medscape.com/Medscape/HIV/Treatment Update/1999). (Visto 8/5/03).
4) Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swenson L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 35(9112): 1328.
5) Crook MA, Mir N. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? Int J STD AIDS 1999; 10(6): 353-6.
6) Carr A, Samaras K, Chisholm D, Cooper D. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998; 351(9119): 1881-3.
7) Gotto A, Assmann G, Carmena R, Davignon J, Fernández Cruz A, Paoletti R. Manual ILIB sobre lípidos para la práctica clínica. Buenos Aires: Waberly Hispánica, 1998; A4: 130-6.
8) Expert Pannel. Summary of the Second Report of tje National Cholesterol Education Program (NCEP) Expert Pannel on Detection, Evaluation, and treatment of High Blooe Cholestyerol in Adults (ATP-ll). JAMA 1993; 269: 3015-23.
9) Sociedad Uruguaya de Ateroesclerosis. 2º Consenso Uruguayo sobre Dislipemias. Agosto de 1998. Red Urug Cardiol 1998: 13(3): 176-204.
10) Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74(5): 1045-52.
11) Christeff N, Lortholary O, Casassus P, Thobie N, Dalle MT, Veyssier P, et al. Serum lipid concentration with reference to the clinical and inmunological status of HIV infected men. Ann Med Interne (Paris) 1995; 146(7): 490-5.
12) Escobar JL, Pinzón JL. Infección y lipoproteínas. Enferm Infecc Microbiol Clin 2000; 18: 83-6.
13) Ducobu J, Payen MC. Lipids and AIDS. Rev Med Brux 2000; 21(1): 11-7.
14) Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of Protease Inhibitors on Hyperglycemia, hyperlipidemia and lipodystrophy: a 5 year cohort study. Arch Intern Med 2000; 160(13): 2050-6.
15) Currier J. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. The AIDS Reader 2000; 10(3): 162-70.
16) Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomised, open label comparision of tjree highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-! Infection: the OzCombo1 study. AIDS 2000; 14(9): 1171-80.
17) Baker R, Kotler D, Carr A, Torres RA. Altered body shape in HIV disease: a side effect of therapy? AIDS Patient Care STDS 1999; 13(7): 395-402.
18) Thiébaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercié P. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, aquitaine cohort, France, 1996 to 1998. J Acquir Immune Defic Syndr 2000; 23(3): 261-5.
19) Pere D, Pérez A, Torres OH, Montiel JA, Vázquez G. Lipodystrophy in HIV-1 infected patients. Lancet 1999; 354(9181): 868.
20) Lai L, Poblet M, Bello C. Are patients with hyperlipidemia being treated? South Med J 2000; 93(3): 283-6.
21) Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 proteasa, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-9.